SCHEMBL476310

SCHEMBL476310

CCOC(=O)c1cnc(Cl)nc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
KDM4E B2RXH2 4/20 0.59
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
HSP90AA1 P07900 1/20 0.49
MAPT P10636 5/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 2/20 0.47
LMNA P02545 1/20 0.47
ATM Q13315 1/20 0.47
SYK P43405 1/20 0.46
NPC1 O15118 3/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.46
TSHR P16473 1/20 0.46
GAA P10253 1/20 0.46
CSNK1D P48730 1/20 0.46
ATF1 P18846 1/20 0.45
NFKB1 P19838 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29922173 1.00 ALDH1A1 (0.59) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
Pyridine SCHEMBL27631572 0.90 ALDH1A1 (0.54) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL23620367 0.87 ALDH1A1 (0.49) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL427402 0.87 ALDH1A1 (0.63) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL31391972 0.87 RAB9A (0.53) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL3435395 0.87 RAB9A (0.53) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL8738554 0.85 KDM4E (0.61) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL14638064 0.85 HSP90AA1 (0.67) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL31379759 0.85 ALDH1A1 (0.51) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL8395110 0.85 ALDH1A1 (0.50) ALDH1A1KDM4EKMT2AMEN1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724442-A1 AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF Council of Scientific and Industrial Research (IN) 2026-04-15 EP claimed
EP-4444293-A2 METHODS OF PREPARING SUBSTITUTED PYRAZOLOPYRIMIDINES KSQ Therapeutics, Inc. (US) 2024-10-16 EP claimed
CN-118369094-A Process for preparing substituted pyrazolopyrimidines KSQ治疗公司 2024-07-19 CN claimed
US-20240116939-A1 CHIRAL OR RACEMIC PYRIMIDINE-FUSED DIAZEPINONE DERIVATIVES, PREPARATION METHOD, AND APPLICATION THEREOF SUN YAT-SEN UNIVERSITY (CN) 2024-04-11 US claimed
WO-2023108048-A2 METHODS OF PREPARING SUBSTITUTED PYRAZOLOPYRIMIDINES KSQ Therapeutics, Inc. (US) 2023-06-15 WO claimed
CN-115368363-A Chiral or racemic pyrimido-diazacycloheptanone compound and preparation method and application thereof 中山大学 2022-11-22 CN claimed
CN-111675694-B Oxime group-containing diaryl pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof 山东大学 2021-11-26 CN claimed
CN-111675694-A Oxime group-containing diaryl pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof 山东大学 2020-09-18 CN claimed
US-4129737-A Process for the preparation of an 8-alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acid LABORATOIRE ROGER BELLON (FR) 1978-12-12 US claimed
CN-122094961-A DNA-dependent protein kinase inhibitors and compositions based on 5, 6-core silacycle and their use in gene editing 2026-05-26 CN disclosed
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECH LIMITED (GB) 2026-05-21 US disclosed
CN-122010902-A Carbonyl substituted pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof 山东大学 2026-05-12 CN disclosed
EP-4727941-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2026-04-22 EP disclosed
EP-4724442-A1 AGONISM-ANTAGONISM IN ENDOSOMAL TLRS BY MODULATING CHEMICAL FEATURES IN 8-OXOPURINE: PROCESS FOR PREPARATION AND APPLICATION THEREOF Council of Scientific and Industrial Research (IN) 2026-04-15 EP disclosed
WO-1999065897-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 1999-12-23 WO disclosed
US-4556709-A BACTERICIDES, FEED ADDITIVES BAYER AKTIENGESELLSCHAFT (DE) 1985-12-03 US disclosed
US-4129737-A Process for the preparation of an 8-alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acid LABORATOIRE ROGER BELLON (FR) 1978-12-12 US disclosed
US-4034094-A 8-Alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acids for treating urinary tract infections LABORATOIRE ROGER BELLOW (FR) 1977-07-05 US disclosed
US-3975384-A ANTITHROMBOTICS BOEHRINGER INGELHEIM GMBH (DT) 1976-08-17 US disclosed
US-3950338-A BACTERICIDES LABORATOIRE ROGER BELLON (FR) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER EGFR, KRAS, O60361 ALDH1A1 999/4885KDM4E 4425/4885KMT2A 3265/4885
US-20240116939-A1 CHIRAL OR RACEMIC PYRIMIDINE-FUSED DIAZEPINONE DERIVATIVES, PREPARATION METHOD, AND APPLICATION THEREOF GRK1, GRIA1, NR3C1 ALDH1A1 2293/4885KDM4E 4452/4885KMT2A 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.